Komipharm International Company Limited operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Komipharm International Company Limited with three other
companies in this sector in South Korea:
ISU Abxis Company Limited
sales of 19.05 billion Korean Won [US$16.71 million]
of which 98%
was Antibody Medicine),
(17.95 billion Korean Won [US$15.74 million]
of which 86%
was The clinical trial agent), and
Choong Ang Vaccine Laboratory
(37.90 billion Korean Won [US$33.24 million]
Komipharm International Company Limited reported sales of 37.64 billion Korean Won (US$33.01 million)
December of 2016.
increase of 3.4%
versus 2015, when the company's sales were 36.41 billion Korean Won.
Sales at Komipharm International Company Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 103%).